Bridge Biotherapeutics, Inc.
Mikyoung Chang has extensive experience in scientific research and project management. Mikyoung has worked at Bridge Biotherapeutics, Inc. as Director, Scientific Affairs and VP Project Management, overseeing Phase 2 clinical trials and regulatory activities. Prior to that, Mikyoung was VP Research at the same company, focusing on preclinical research for new drug development projects. Earlier in their career, Mikyoung worked at MD Anderson Cancer Center as a Research Faculty Instructor and Post Doctoral Fellow, conducting research on immune and inflammatory responses. Mikyoung holds a Ph.D. in Genetics/Immunology and microbiology from Penn State University.
This person is not in any offices
Bridge Biotherapeutics, Inc.
Bridge Biotherapeutics, Inc. is a virtually-operated, venture-backed clinical stage global biotech company, headquartered in Seongnam, Korea with its subsidiary at JLABS@TMC, engaged in the development of novel therapeutics, focusing on therapeutic areas of high unmet medical needs, such as ulcerative colitis, fibrotic diseases, and cancers.